Text Versions

Updates and reauthorizes a broad set of federal prevention, treatment, and recovery activities for substance use and mental-health care through FY2026–2030. It increases or redirects funding for multiple programs, creates/clarifies peer-support technical assistance (including a new regional center), requires a range of studies and reports, and sets new program and reporting deadlines for HHS, FDA, DEA, and related agencies. Also changes selected Controlled Substances Act and pharmacy rules to permit certain deliveries to prescribing practitioners and revises prescriber-training language; it adds programmatic flexibilities (e.g., limited use of recovery grant funds for transportation), new evaluation and oversight requirements, and deadlines for agency guidance and reviews.

Key Points

Reauthorizes and adjusts funding and rules for prevention, treatment, and recovery programs for SUD and mental health for FY2026–2030.
Requires multiple reports, studies, and program evaluations by HHS, FDA, and DEA, with specific deadlines and Congressional notifications.
Creates/expands peer‑support technical assistance including a new regional center with evaluation and a set termination date.
Permits limited use of recovery grant funds (e.g., transportation) and clarifies application, reporting, and definition rules for grantees.
Allows pharmacies to deliver certain Schedule III–V medications to prescribing practitioners for maintenance/detox or REMS‑monitored drugs under defined conditions.
Directs review/report on buprenorphine/naloxone scheduling and other medication‑access issues to inform federal policy.
Updates prescriber‑training statutory language to broaden/clarify covered medical fields and accredited training programs.
Imposes new oversight, data, and reporting obligations that will change administrative work for federal agencies and grantees.
Focuses heavily on prevention (prenatal/postnatal care, FASD, suicide‑lifeline security, overdose prevention) alongside clinical treatment and recovery.

Categories & Tags

Funding

$926.6M authorized

Agencies

Department of Health and Human Services (HHS)

Food and Drug Administration (FDA)

Drug Enforcement Administration (DEA)

Comptroller General (GAO)

Assistant Secretary (HHS)

Provisions

58 items

Amends Section 317L(d) of the Public Health Service Act to set funding at $4,250,000 for each of fiscal years 2026 through 2030 for the prenatal and postnatal health program.

authorization

$4.3MAffects: Prenatal and postnatal health program/Section 317L (HHS) (program-level funding)

Amends Section 317N(d) of the Public Health Service Act to change references to the program years from fiscal years 2019–2023 to fiscal years 2026–2030 for monitoring and education regarding infections associated with illicit drug use and other risk factors.

amendment

Affects: Monitoring and education program under Section 317N (HHS)

Makes textual and program changes to Section 392A of the Public Health Service Act to broaden language (e.g., replacing “opioids” with “substances causing overdose”) and to change internal wording such as changing “coding” to “monitoring and identifying.”

amendment

Affects: Programs authorized under Section 392A (grantees and HHS activities to prevent overdoses)

Amends Section 392A(a)(3) to add or clarify that grants may fund innovative projects to detect, identify, and rapidly respond to controlled substance misuse, abuse, and overdoses; such projects may include evidence-based strategies like wastewater surveillance if proven to support actionable prevention strategies and consistent with Federal and State privacy laws.

authorization

Affects: Grantees (States, Tribes) carrying out detection and response projects under Section 392A

Amends Section 392A(e) to authorize $505,579,000 for each of fiscal years 2026 through 2030 (replacing the prior $496,000,000 for each fiscal year 2019–2023) for activities under Section 392A.

authorization

$505.6MAffects: Programs funded under Section 392A (HHS grants/activities to prevent overdoses)

Laws This Bill Would Affect

11 amendments6 references

Amends42 U.S.C. 290ll

Amends the Minority Fellowship Program statute (section 597 of the Public Health Service Act) in subsections (a)(1) and (b) (specific inserted language not shown in the excerpt).

References21 U.S.C. 811

References the Controlled Substances Act procedures and criteria for scheduling decisions as the standard for HHS and the Attorney General to use when reviewing buprenorphine/naloxone product scheduling.

References21 U.S.C. 355

References FDCA section 505 (new drug approval) to define which opioid overdose reversal drugs must be included in HHS grant program regulations and guidance (FDA-approved under section 505).

References21 U.S.C. 823

Cites 21 U.S.C. 823 in connection with amendments to SUPPORT Act section 3203 (a note associated with registration requirements), but does not directly amend the USC text in this excerpt.

Amends42 U.S.C. 295h

Amends the authorization level in subsection (j) for the loan repayment program for the substance use disorder treatment workforce, increasing the authorized amount and updating fiscal years.

Amends21 U.S.C. 829a(a)

Strikes paragraph (2) of subsection (a) and inserts a revised paragraph (2) describing the Schedule III–V drug administration conditions (injection/implantation for maintenance or detoxification treatment, or subject to a REMS with elements to assure safe use including post-administration monitoring).

Amends42 U.S.C. 290ee–2(f)

Replaces the authorization amount and fiscal-year range in section 547(f) (Building Communities of Recovery).

Amends42 U.S.C. 290ee–2a

Updates activities in subsection (b)(4), redesignates subsections, adds a Regional Center subsection with evaluation/reporting and a termination date, and updates the fiscal-year authorization period in subsection (f) (amount text garbled).

Amends42 U.S.C. 290ee–7

Modifies application content language, capability language for carrying out activities through referral/contractual arrangements, adds additional reporting for entities using referral/contractual arrangements, restructures subsection (h), and updates the authorization period to FY2026–FY2030.

Amends42 U.S.C. 290bb–7a(c)

Updates definitions and terms for the youth prevention and recovery grant provisions, including defining 'secondary school' by reference to 20 U.S.C. 7801 and defining 'Indian Tribe' and 'Tribal organization' by reference to 25 U.S.C. 5304, and authorizes appropriations for FY2026–FY2030 with specified amounts.

And 7 more affected sections...

Text Versions

Text as it was Enrolled Bill

September 20, 2025

View

Text as it was Referred in Senate

June 5, 2025

View

Text as it was Engrossed in House

June 4, 2025

View

Text as it was Reported in House

May 29, 2025

View

Text as it was Introduced in House

March 31, 2025

View

Amendments

HAMDT 25June 4, 2025An amendment numbered 3 printed in Part A of House Report 119-130 to codify Biden-era guidance to ensure that budget neutrality requirements for Section 1115 Waivers take into account downstream savings.

HAMDT 26June 4, 2025An amendment numbered 4 printed in Part A of House Report 119-130 to require HHS to convene a public meeting to improve awareness of, access to, and information related to funding opportunities related to mental health and SUD programs of SAMHSA grant programs.

HAMDT 23June 4, 2025An amendment numbered 1 printed in Part A of House Report 119-130 to require all HHS regulations or guidance documentation to use language that is inclusive of all opioid overdose reversal drugs that have been approved by FDA, instead of referring to brand names.

HAMDT 24June 4, 2025An amendment numbered 2 printed in Part A of House Report 119-130 to require the Office of the National Coordinator to convene a public roundtable to examine how the expanded use of electronic health records among mental health and substance use service providers can improve outcomes for patients in mental health and substance use disorder settings and how best to increase Electronic Health Record adoption among such providers.

Text Versions

SUPPORT for Patients and Communities Reauthorization Act of 2025

Sponsors (2)

Committee Meetings